NTCIR-17 kickoff event Sept 28, 2022

# NTCIR-17 Medical Natural Language Processing for Social media and Clinical texts (MedNLP-SC)

Eiji Aramaki, Ph.D. (NAIST, Japan) Co-chair (general) Shoko Wakamiya, Ph.D. (NAIST, Japan) Co-chair (general) Shuntaro Yada, Ph.D. (NAIST, Japan) Co-chair (Subtask SM) Yuta Nakamura, M.D. (The University of Tokyo, Japan) Co-chair (Subtasks RR)

## MedNLP series

Name	Text	Task	Languages
NTCIR-10 MedNLP pilot	Dummy health records (by hand)	NER	JA •
NTCIR-11 MedNLP-2	Dummy health records (from examinations)	NER, NEN	JA •
NTCIR-12 MedNLPDoc	Dummy health records (from the textbook)	ICD coding	JA •
NTCIR-13 MedWeb	Dummy social media texts (created by crowdsourcing)	Phenotyping	JA • EN EN ZH
NTCIR-16 Real-MedNLP	Real health records: Case reports and Radiology reports	NER, ADE, CI	JA • EN
NTCIR-17 MedNLP-SC Social Media (SM)	Dummy social media texts (SM)	ADE	JA • EN EN DE EN
NTCIR-17 MedNLP-SC Radiology Report (RR)	Real health records: Radiology reports (RR)	NER, TNM	JA •

Named Entity Recognition (NER) Named Entity Normalization (NEN) Adverse Drug Event detection (ADE) Case Identification (CI) (MedNLP original task)
TNM cancer staging (TNM) (MedNLP original task)

## MedNLP-SC subtasks

Information extraction from medical reports written by physicians or social media data

- Subtask for Social Media (SM)
  - Adverse drug event detection (ADE)
  - Text: Social media data (n=20,000 artificial tweets)
  - Language: Japanese , English , French , and German
- Subtasks for Radiology Report (RR)
  - (a) Named Entity Recognition (NER)
  - (b) TNM staging (TNM)
  - Text: Radiology reports (n=135 reports or more)
  - Language: Japanese 🐞

## Social media data (tweets)

- Create a Japanese corpus consisting of 20,000 artificial tweets
  - Out of a maximum of 68,000 artificial tweets (= 68 drugs x 1000 tweets) generated using T5
  - Each tweet is manually checked and annotated symptom label(s)
- Translate the corpus into the other three languages by machine translation with manual check
  - All language shares the same symptom label(s)

Samples of symptom labels

Label	Japanese •	English	French	German
PAIN	疼痛	pain	douleur	Schmerzen
CONSTIPATION	便秘	constipation	constipation	Verstopfung
DIARRHEA	下痢	diarrhea	diarrhée	Diarrhöe
NAUSEA	吐き気	nausea	nausées	Übelkeit
VOMITING	嘔吐	vomiting	vomissements	vomissements 4

# Artificial tweet samples of "gamma globulin" (1/2)

#### Example 1

検索もせずただひたすら我慢してるだけマシなんだが…。γグロブリン大量投与で一発 逆転できるのかしら、それともガンマグロブリン大量投与か……ってなると何回やって も思い出せない

(I'm better off not searching for it and just holding on... I wonder if a large dose of **gamma globulin** would turn it around, or a large dose of **gamma globulin**. ..... I can't remember how many times I've tried.) translated by DeepL

#### Example 2: No drug name

持病の関係で昨日病院行ったら血液検査の結果が出て「リンパ球減少症」と診断されました¥nでも今日からまた薬が増えます~!頑張れ私!!'

(I went to the hospital yesterday because of my chronic illness and the results of my blood test came back and I was diagnosed as "lymphopenia." Hang in there me!)

translated by DeepL

# Artificial tweet samples of "gamma globulin" (2/2)

• Example 3: No ADE

けど、このところ連日の高熱が続きすぎて辛いです…今夜も頑張って寝ます!(\*^^\*)今日は病院に行って血液検査と**γグロブリン**注射をしてきました。これで少しでも良くなりますように!!お騒がせしましたm(=\_=;")早く元気になって欲しいものです

(But I'm having a hard time because I've had too many high fevers in a row recently... I will try my best to sleep tonight! (\*^^\*) I went to the hospital today for a blood test and a **gamma globulin** shot. I hope this will make me feel a little better! Sorry for the trouble  $m(=_=;")$ I hope she gets well soon!) translated by DeepL

• Example 4: Just mentioned

<user\_name> さん、こんにちは。私も昨日2回目打ってきましたよ!\*n接種後から頭痛と熱っぽさが出ていたので $\gamma$ グロブリン製剤を飲むように指示されたそうです。'

(Hello, <user\_name>. I got my second shot yesterday too! ¥They told me to take a **gamma globulin** preparation because I had a headache and feverishness since after the **o**n vaccination.') <sub>translated by DeepL</sub>

## Adverse Drug Event detection (SM-ADE)

 Multi-labeling task to identify a set of symptoms caused by a drug (section)

Given an input sentence in the section of FU5:

"After FU5 starts, I am suffering from dry cough and many mouth ulcers."

The expected output labels:

"dry cough" and "mouth ulcers"

• Similar to hashtag recommendation because symptom label(s) can be represented as hashtags

e.g., "After FU5 starts, I am suffering from dry cough and many mouth ulcers. #dry\_cough #mouth\_ulcers"

## FAQ for Social Media Subtask

- (a) The performance of T5 to create tweet-like short messages Answer: To ensure that the artificial tweets are sufficiently similar to real ones, we will conduct the Turing Test, which annotators determine whether a tweet is real or artificial
- (b) The quality of the artificial tweets

  Answer: To keep the quality of our dataset, artificial tweets will be checked by annotators and modified/removed if not appropriate
- (c) The appropriateness of applying machine translation


  Answer: Due to the cost (both time and money), we will employ machine translation
- (d) Evaluation methods
  Answer: We plan to employ F-measure

image: https://radiopaedia.org/cases/cavitating-lung-cancer-1 Report: J-MedStd RR

## MedTxt-RR Corpus

A set of radiology reports of the same cancer cases diagnosed by different radiologists independently

- The latest version contains 135 texts for 15 cases and 9 radiologists, some of which are already available at <a href="https://sociocom.naist.jp/medtxt/rr/">https://sociocom.naist.jp/medtxt/rr/</a>
- We are planning to make the dataset larger by recruiting additional cancer cases and radiologists



#### Radiologist A's report

両肺には軽度の気腫性変化、左肺上葉外側にbulla を認めます。

左肺下葉には内部に空洞を伴う長径7.8cm 大の不整形腫瘤を認め、

同一肺葉内には副結節を疑う複数の病変を認めます(cT4)。

腫瘤は胸膜と広範に接しており、胸膜外脂肪層も 一部途絶が見られ、壁側胸膜浸潤を疑います。

肋骨への浸潤ははっきりしません。 腫瘤は横隔膜とも一部接していますが、浸潤所見 ははっきりしません。

左肺門や気管分岐下や大動脈下などの同側の縦隔

#### Radiologist B's report

癌と考えます。

左肺下葉に長径78mm大の腫瘤があり、既知の肺

左肺下葉中枢側にはsatellite lesionと思われる結 節を複数認めます。

胸壁に広く接しており、胸壁脂肪織の消失も認められ、胸壁に浸潤している可能性もあります。

9

左肺門部、気管分岐下、左下部気管傍リンパ節が






## (a) Named Entity Recognition (RR-NER)

## Guideline Learning (proposed in Subtask 2 of NTCIR-16 Real-MedNLP)

- Provide only the guideline text for human annotators
  - 30-40 example sentences annotated
  - A sample of annotation guideline is available at <a href="https://sociocom.naist.jp/real-mednlp">https://sociocom.naist.jp/real-mednlp</a>
- Participants can use any other resources outside this task if they find them useful for their methods
- Can we teach a model as if it is a human?



```
A左上葉 に 「径 1 8 mm 「大 の Dt 1 S S N を認めます。 D(?) A A H や A I S の可能性があります。 A右下葉 にも D(+) G G N を 「散見 します。 D(?) 炎症性変化 かもしれませんが、フォローにて D(+) 変化 をご確認ください。 A左下葉 に D(+) 線状索状影 を認め D(?) 陳旧性炎症性変化 が疑われます。 A縦隔や肺門 に 同有意な D(-) リンパ節腫大 は指摘できません。 D(-) 胸水 はありません。
```

- Diseases and symptoms <d>
- Anatomical entities <a>
- Features and measurements <f>
- Change <c>
- Time <timex3>

- Test <t-test/key/val>
- Medicine <m-key/val>
- Remedy <r>
- Clinical Context <cc>

## (b) TNM staging (RR-TNM)

To evaluate the generalization ability of NLP models when classifying radiology reports under multiple criteria (cancer staging)

According to predefined criteria, participant systems assign four labels

- tumor(T) 原発のがんの広がり
- lymph node (N) がん細胞のリンパ節への転移の有無と広がり
- metastasis (M) 原発から離れた臓器への遠隔転移
- clinical stage (cStage)

#### e.g.,

- Early cancers will be labeled with small numbers such as T1N0M0, cStage 1
- Advanced ones will be labeled with large numbers such as T3N2M1, cStage 4

## FAQ for Radiology Report Subtasks

#### (a) How to build dataset

Answer: We collaborate with a teleradiology company and use an openaccess radiology case repository. Radiology reports are written by radiologists diagnosing real, public, and anonymized cancer images.

#### (b) The dataset size

Answer: We are working on adding data, which will make the current dataset (n=135) larger.

#### (c) RR-TNM: definition of cancer stage

Answer: We follow the Union for International Cancer Control (UICC) criteria as clinicians do. We are planning to use the 7<sup>th</sup> and 8<sup>th</sup> editions to simulate revision.

## Collaboration

To develop high-quality multilingual data, we collaborate with researchers from DFKI (Germany), LISN-CNRS (France), and RIKEN and NII (Japan)

- Akiko Aizawa, Ph.D. (NII, Japan)
- Gabriel Herman Bernardim Andrade (NAIST, Japan)
- Cyril Grouin, Ph.D. (Université Paris-Saclay, CNRS, LISN, France)
- Shouhei Hanaoka, MD, PhD (The University of Tokyo, Japan)
- Thomas Lavergne, Ph.D. (Université Paris-Saclay, ČNRS, LISN, France)
- Yuji Matsumoto, Ph.D. (RIKEN, Japan)
- Faith Wavinya Mutinda (NAIST, Japan)
- Aurélie Névéol, Ph.D. (Université Paris-Saclay, CNRS, LISN, France)
- Noriaki Nishida, Ph.D. (RIKEN, Japan)
- Tomohiro Nishiyama (NAIST, Japan)
- Patrick Paroubek, Ph.D. (Université Paris-Saclay, CNRS, LISN, France)
- Lisa Raithel (DFKI, Germany)
- Roland Roller, Ph.D. (DFKI, Germany)
- Hiroki Teranishi, Ph.D. (RIKEN, Japan)
- Philippe Thomas, Ph.D. (DFKI, Germany)
- Narumi Tokunaga (RIKEN, Japan)
- Hui-Syuan Yeh (Université Paris-Saclay, CNRS, LISN, France)
- Pierre Zweigenbaum, Ph.D. (Université Paris-Saclay, CNRS, LISN, France)

### Tentative Schedule

- March 2023: Dataset Release
- (March-June 2023: Dry Run)
- June 1, 2023: Registration Deadline
- July 2023: Formal Run
- August 1, 2023: Evaluation Result Release
- August 1, 2023: Task overview paper release (draft)
- September 1, 2023: Submission due of participant papers (draft)
- November 1, 2023: Camera-ready participant paper due
- December 2023: NTCIR-17 Conference in NII, Tokyo